Cingulate Inc. (CING): רווח נקי למניה ב-12 החודשים האחרונים
Cingulate Inc. develops therapies for ADHD and anxiety utilizing extended-release methods. Net income per share TTM demonstrates fundamental stability, where the parameter value equals -3.64. CTR patents and strict FDA oversight serve as business protections, while growth relies on the collection of clinical test data within the R&D platform.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_CING_-_Cingulate-Inc._-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) Cingulate Inc. (CING): לתקופה 04.07.2022 - 10.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Cingulate Inc (CING)
Amid market uncertainty, investors prioritize seeking assets with proven returns. This metric measures net income distributed per share, allowing for an assessment of real capital efficiency regardless of the issuance volume. By analyzing the net income per share over the last 12 months, one can determine the business's resilience to borrowing costs. For Cingulate Inc. (CING), this indicator reflects financial results in the absence of heavy capital expenditures. Outsourcing production and testing makes profit dynamics more sensitive to the operational successes of the scientific team.
